Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABI H2158

Drug Profile

ABI H2158

Alternative Names: 2158; ABI-2158; ABI-H2158

Latest Information Update: 12 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences; Indiana University
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 04 Nov 2019 Assembly Biosciences plans a phase I trial for Hepatitis B (In volunteers) in China (PO) (NCT04142762)
  • 16 Oct 2019 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Hepatitis B released by Assembly Biosciences
  • 07 Oct 2019 Assembly Biosciences completes a pharmacokinetic phase I trial for Hepatitis B (In volunteers) in USA (PO) (NCT04083716)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top